DDInter1506 DDInter1180
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Pramlintide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Pramlintide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Corticotropin
Pramlintide {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Pramlintide may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Pramlintide may lead to a major life threatening interaction when taken with Gatifloxacin